Developer docs
API playgroundTry for free, no card

Search company profiles

Athira Pharma

Full company profile

uuid0002gzg

Namestring
Athira Pharma
Legal namestring
Athira Pharma, Inc.
Websiteurl
athira.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Athira Pharma, Inc., now operating as LeonaBio, is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, listed on NASDAQ under ticker ATHA. The company develops novel small molecule drug candidates targeting devastating diseases with limited treatment options, with two lead programs: lasofoxifene, a selective estrogen receptor modulator (SERM) currently in Phase 3 development (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for amyotrophic lateral sclerosis (ALS) that has completed Phase 1 trials in healthy volunteers.

Athira's commercial model is preclinical-stage clinical biopharma: it does not yet generate revenue from product sales and instead finances operations through equity capital, with the most recent transaction being a December 2025 private placement of $90 million (up to $236 million contingent on a regulatory milestone) co-led by Perceptive Advisors, extending cash runway into 2028. The strategic license-in of lasofoxifene from Sermonix Pharmaceuticals in December 2025 repositioned the company from a neurodegenerative-disease-focused pipeline (Alzheimer's/ALS) toward oncology, with lasofoxifene representing the primary value driver and projected by management to achieve peak annual U.S. sales of approximately $1 billion if approved. Topline Phase 3 data for ELAINE-3 is expected in mid-2027.

Upon regulatory approval, Athira/LeonaBio intends to commercialize lasofoxifene through specialty pharmaceutical distribution channels (specialty pharmacies and oncology-focused institutions) across global markets excluding Asia and certain Middle Eastern countries. The company has not yet established commercial infrastructure for direct product sales and currently markets to investors and medical/scientific audiences through investor relations communications, conference presentations (e.g., 5th Annual ALS Drug Development Summit), and medical affairs activities.

Short descriptiontext

Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule therapies, with a Phase 3 SERM (lasofoxifene) for metastatic breast cancer and a Phase 1 ALS candidate (ATH-1105), serving patients with high-unmet-need oncology and neurodegenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBothell, United States
HQ citystring
Bothell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, clinical stage biopharmaceutical, oncology drug development, neurodegenerative disease therapeutics, selective estrogen receptor modulators
Industry3 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-Stage Biopharmaceutical Drugs
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Future revenue will be generated through commercialization of approved drug candidates, including lasofoxifene for metastatic breast cancer and ATH-1105 for ALS, if regulatory approvals are obtained.

defenseworld.net
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for ALS that completed Phase 1 studies. The company in-licensed lasofoxifene from Sermonix Pharmaceuticals in December 2025 and is funded to advance through topline Phase 3 data in mid-2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 ELAINE-3 trial more than 50% enrolled with topline data expected mid-2027
+2 more records
Product overview1 text field

LeonaBio (formerly Athira Pharma) is a late-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company operates two lead programs: lasofoxifene (Phase 3, for metastatic breast cancer) and ATH-1105 (Phase 1 completed, for ALS). The portfolio focuses on neurodegenerative diseases and oncology, with strategic licensing of Phase 3 assets to expand the pipeline.

Product and service2 records
1Lasofoxifene
CategoryOncology drug candidate - SERM
Description

A novel, oral small molecule selective estrogen receptor modulator (SERM) currently in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer. The drug candidate aims to establish a potential new standard of care with peak annual U.S. sales projected at approximately $1 billion. In-licensed from Sermonix Pharmaceuticals; originally developed by Pfizer.

2ATH-1105
CategoryNeurodegenerative disease drug candidate
Description

A novel, small molecule drug candidate for ALS (amyotrophic lateral sclerosis) that completed a Phase 1 clinical trial in healthy volunteers, showing positive safety and pharmacokinetic results. The company continues to advance this therapeutic candidate for neurodegenerative disease treatment.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Exclusive global license (excluding Asia and certain Middle Eastern countries) to develop and commercialize lasofoxifene, a Phase 3 selective estrogen receptor modulator for metastatic breast cancer. Deal terms include approximately $34.9 million in equity issuance, $16.8 million in third-party payments, monthly payments of $75,000 creditable against potential milestones totaling $100 million. Pfizer originally developed the asset and returned rights to Ligand Pharmaceuticals after a 2009 FDA complete response letter, with Sermonix later in-licensing the asset.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors32 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Athira Pharma

Clinical-Stage Biopharmaceutical Drugsathira.com

Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule therapies, with a Phase 3 SERM (lasofoxifene) for metastatic breast cancer and a Phase 1 ALS candidate (ATH-1105), serving patients with high-unmet-need oncology and neurodegenerative diseases.

What Athira Pharma does

Athira Pharma, Inc., now operating as LeonaBio, is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, listed on NASDAQ under ticker ATHA. The company develops novel small molecule drug candidates targeting devastating diseases with limited treatment options, with two lead programs: lasofoxifene, a selective estrogen receptor modulator (SERM) currently in Phase 3 development (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for amyotrophic lateral sclerosis (ALS) that has completed Phase 1 trials in healthy volunteers.

Athira's commercial model is preclinical-stage clinical biopharma: it does not yet generate revenue from product sales and instead finances operations through equity capital, with the most recent transaction being a December 2025 private placement of $90 million (up to $236 million contingent on a regulatory milestone) co-led by Perceptive Advisors, extending cash runway into 2028. The strategic license-in of lasofoxifene from Sermonix Pharmaceuticals in December 2025 repositioned the company from a neurodegenerative-disease-focused pipeline (Alzheimer's/ALS) toward oncology, with lasofoxifene representing the primary value driver and projected by management to achieve peak annual U.S. sales of approximately $1 billion if approved. Topline Phase 3 data for ELAINE-3 is expected in mid-2027.

Upon regulatory approval, Athira/LeonaBio intends to commercialize lasofoxifene through specialty pharmaceutical distribution channels (specialty pharmacies and oncology-focused institutions) across global markets excluding Asia and certain Middle Eastern countries. The company has not yet established commercial infrastructure for direct product sales and currently markets to investors and medical/scientific audiences through investor relations communications, conference presentations (e.g., 5th Annual ALS Drug Development Summit), and medical affairs activities.

Athira Pharma firmographics

Firmographics
Name
Athira Pharma
Legal name
Athira Pharma, Inc.
Website
https://athira.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule therapies, with a Phase 3 SERM (lasofoxifene) for metastatic breast cancer and a Phase 1 ALS candidate (ATH-1105), serving patients with high-unmet-need oncology and neurodegenerative diseases.
Ownership category
akta.pro rank

Athira Pharma industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Drugs
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Clinical stage biopharmaceutical
  • Oncology drug development
  • Neurodegenerative disease therapeutics
  • Selective estrogen receptor modulators

Where Athira Pharma is headquartered

Location

Headquarters

HQ city
Bothell
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Athira Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug commercialization: Pre-revenue clinical-stage biopharmaceutical company. Future revenue will be generated through commercialization of approved drug candidates, including lasofoxifene for metastatic breast cancer and ATH-1105 for ALS, if regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Athira Pharma product offering

Product offering

Core offering

Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for ALS that completed Phase 1 studies. The company in-licensed lasofoxifene from Sermonix Pharmaceuticals in December 2025 and is funded to advance through topline Phase 3 data in mid-2027.

Product overview

LeonaBio (formerly Athira Pharma) is a late-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company operates two lead programs: lasofoxifene (Phase 3, for metastatic breast cancer) and ATH-1105 (Phase 1 completed, for ALS). The portfolio focuses on neurodegenerative diseases and oncology, with strategic licensing of Phase 3 assets to expand the pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lasofoxifene A novel, oral small molecule selective estrogen receptor modulator (SERM) currently in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer. The drug candidate aims to establish a potential new standard of care with peak annual U.S. sales projected at approximately $1 billion. In-licensed from Sermonix Pharmaceuticals; originally developed by Pfizer.
  • ATH-1105 A novel, small molecule drug candidate for ALS (amyotrophic lateral sclerosis) that completed a Phase 1 clinical trial in healthy volunteers, showing positive safety and pharmacokinetic results. The company continues to advance this therapeutic candidate for neurodegenerative disease treatment.

Quantifiable outcome

  • Phase 3 ELAINE-3 trial more than 50% enrolled with topline data expected mid-2027
  • +2 more outcomes

Companies that use Athira Pharma

Customer profile

Segments2 records

Ideal customer profiles1 record

Athira Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Athira Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sermonix PharmaceuticalscoreStrategic or Co-development Partner · 18 December 2025Exclusive global license (excluding Asia and certain Middle Eastern countries) to develop and commercialize lasofoxifene, a Phase 3 selective estrogen receptor modulator for metastatic breast cancer. Deal terms include approximately $34.9 million in equity issuance, $16.8 million in third-party payments, monthly payments of $75,000 creditable against potential milestones totaling $100 million. Pfizer originally developed the asset and returned rights to Ligand Pharmaceuticals after a 2009 FDA complete response letter, with Sermonix later in-licensing the asset.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Athira Pharma competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Athira Pharma social profiles

Digital presence

Athira Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Athira Pharma leadership team

Management profile

Number of profiles

Profiles8 records

Athira Pharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Athira Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Athira Pharma

What does Athira Pharma do?

Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for ALS that completed Phase 1 studies. The company in-licensed lasofoxifene from Sermonix Pharmaceuticals in December 2025 and is funded to advance through topline Phase 3 data in mid-2027.

Is Athira Pharma a public or private company?

Athira Pharma is a public company. It is classified as public and is currently operating.

When was Athira Pharma founded?

Athira Pharma was founded in 2011. It employs 51 to 100 people.

Where is Athira Pharma based?

Athira Pharma is headquartered in Bothell, United States, in the North America region.

How does Athira Pharma make money?

One revenue line is on record: drug commercialization.

Does Athira Pharma have an API?

No public API is recorded for Athira Pharma.

What industry is Athira Pharma in?

Athira Pharma's product category is Clinical-Stage Biopharmaceutical Drugs. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportAthira Pharma, Inc. (NASDAQ:LONA) Sees Significant Increase in Short InterestAthira Pharma's short interest surged 355.7% to 87,344 shares as of October 15th, representing 1.3% of shares sold short. The stock opened at $4.89, with a consensus price target of $17.33 and a Moderate Buy rating. Analysts forecast a -2.67 EPS for the current year.American Banking and Market NewsAthira Pharma, Inc. (LONA) – What Are Investment Firms Saying About This Stock?Athira Pharma received a consensus 'Moderate Buy' rating from six analysts, with an average 12-month price target of $17.33. The stock opened at $4.84, and the company reported a Q2 loss of $0.80 per share, missing the $0.60 consensus estimate. Analysts forecast a current-year loss of $2.67 per share.American Banking and Market NewsAthira Pharma (NASDAQ:LONA) Upgraded to “Hold” at Wall Street ZenWall Street Zen upgraded Athira Pharma to a Hold rating. The company's consensus rating is Moderate Buy with an average target price of $17.33, and shares opened at $5.20. Analysts forecast a fiscal-year EPS of -$2.67.Ticker ReportAthira Pharma, Inc. (NASDAQ:LONA) Short Interest UpdateAthira Pharma's short interest fell 41.3% to 23,651 shares as of September 15th. Analysts rate the stock a Moderate Buy with a consensus price target of $17.33, while institutional investors hold 57.12% of shares. The company reported a Q2 loss of $0.80 per share, missing estimates.American Banking and Market NewsCitizens Jmp Issues Pessimistic Forecast for Athira Pharma (NASDAQ:LONA) Stock PriceCitizens Jmp lowered its price target for Athira Pharma from $18.00 to $17.00 while maintaining a "market outperform" rating on the stock. Other analysts recently adjusted their ratings or initiated coverage, with MarketBeat data showing an average target price of $15.67 and a "Moderate Buy" consensus. The report also notes that institutional investors have increased their stakes in the company during recent quarters.Defense WorldAthira Pharma (NASDAQ:ATHA) Trading 6.3% Higher – Here’s What HappenedAthira Pharma shares traded up 6.3% during Wednesday trading, reaching a high of $11.91 before settling at $11.68, with 41,461 shares traded compared to the average session volume of 3.2 million shares. The clinical-stage biopharmaceutical company, which focuses on developing therapies for neurodegenerative diseases using the HGF/MET pathway, has a market cap of $46.07 million. Several institutional investors, including Millennium Management LLC ($2.46 million stake), Renaissance Technologies LLC (44.7% stake increase), and Seven Fleet Capital Management LP ($969,000 stake), disclosed new or expanded positions during the fourth quarter.Defense WorldReviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)This article compares two small-cap biopharmaceutical companies, InflaRx N.V. and Athira Pharma, Inc., across 12 financial and investment metrics including risk, valuation, earnings, and analyst recommendations. InflaRx emerged superior on 8 of the 12 factors, with higher revenue, lower net losses, a lower price-to-earnings ratio, and a higher consensus price target indicating 563% potential upside versus Athira's 55% potential downside. The comparison indicates research analysts favor InflaRx over Athira Pharma based on current market positioning and financial metrics.Defense WorldFinancial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)This article presents a side-by-side financial comparison of two small-cap companies: Athira Pharma and Prime Medicine. The analysis contrasts metrics including revenue, earnings per share, valuation, institutional ownership, analyst recommendations, and profitability. Prime Medicine outperformed Athira Pharma on 8 of 14 comparative factors, though both companies are unprofitable with negative earnings and net margins.Defense WorldAthira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head AnalysisThis article provides a comparative investment analysis between Athira Pharma and Liminatus Pharma, two small-cap pharmaceutical companies, examining metrics including revenue, earnings, institutional ownership, and analyst ratings. Athira Pharma, a late clinical-stage biopharmaceutical company developing treatments for Alzheimer's and Parkinson's disease, scored higher on 6 of 9 comparison factors with a consensus target price of $10.00 and analyst rating of 2.25. Liminatus Pharma, a pre-clinical stage immuno-oncology company, received a lower analyst rating of 1.00 and is trading at a more affordable price-to-earnings ratio.StocktwitsAthira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally?Athira Pharma secured exclusive global rights to the Phase 3 breast cancer drug lasofoxifene from Sermonix Pharmaceuticals and announced a $236 million financing package to support its development. The company raised an upfront $90 million through private placement, with potential additional proceeds of $146 million via warrant exercises, while agreeing to milestone payments and royalties for Sermonix. This strategic move triggered a over 60% surge in Athira's stock price as it prepares for clinical data expected in mid-2027.